Platelets as Programmable Drug Depots: Toward Predictive and Mechanistic Drug Loading

Clinical Snapshot

Key Findings

• Effect Size: Not reported — no experimental data presented

• Primary Outcome: Conceptual proposal only: platelet granules can serve as programmable drug depots whose loading is predictable via physicochemical modelling (ion trapping of weakly basic drugs in acidic granules, pKa-dependent) and active transporter-mediated uptake (vesicular monoamine and nucleotide transporters)

• Nnt Or Sensitivity: Not applicable at this stage; no clinical or diagnostic performance data. Future validation studies would need to report loading efficiency ratios, transporter affinity constants (Km, Vmax), and in vivo drug release profiles

• Confidence Interval: Not applicable — no quantitative results

Clinical Application

Currently not feasible for clinical application. The framework is at Technology Readiness Level 1-2 (basic principles observed; technology concept formulated). Significant preclinical validation is required before IND-enabling studies. Manufacturing of autologous or allogeneic drug-loaded platelets at clinical scale presents substantial GMP challenges. Shelf-life of platelets (5-7 days) limits logistical feasibility for non-acute indications. No current TGA-approved platelet-based drug delivery products exist in Australia. This research is not yet relevant to PBS listing or RACGP clinical guidelines. The concept may have future relevance to Australian haematology and oncology practice given Australia's established platelet transfusion infrastructure (Australian Red Cross Lifeblood). RACGP and ANZICS guidelines on platelet transfusion would need to be substantially revised before any clinical translation. Australian researchers at institutions such as the Peter MacCallum Cancer Centre and WEHI have active platelet biology programmes that could provide relevant collaborative validation platforms. TGA's biologics regulatory framework (under the Therapeutic Goods Act 1989) would classify drug-loaded platelets as a combination biological-drug product, requiring a complex regulatory pathway. Theoretically applicable to any patient population where targeted drug delivery via circulating platelets would be advantageous — particularly oncology (tumour microenvironment platelet accumulation), cardiovascular disease, and inflammatory conditions. Platelet-rich environments at sites of vascular injury or tumour stroma represent logical targets.

Abstract

Efficient drug delivery remains a major challenge in pharmaceutical science, with synthetic nanocarriers often facing limitations in real biological systems. While blood platelets have been explored as biomimetic carriers, their intrinsic capacity for molecular storage and stimulus-triggered release remains largely underutilized. Here, we propose that platelet granules can be viewed as programmable drug depots, whose loading can be rationally controlled using physicochemical principles and endogenous transport mechanisms. In contrast to empirical approaches, we outline a framework based on two complementary pathways: passive accumulation driven by ion trapping of weakly basic compounds in acidic granules, and active uptake mediated by vesicular transporters. Building on recent advances in structural biology and computational modeling, we further argue that drug loading into platelets can be predicted and optimized using molecular descriptors, docking approaches, and machine learning models to estimate transporter compatibility and accumulation efficiency. This perspective introduces a conceptual design loop linking prediction and molecular optimization─i.e., enabling both selection of suitable drug candidates and rational modification of their structures to enhance platelet compatibility. Together, these concepts position platelets not simply as biomimetic carriers but as model-guided and engineerable platforms for drug delivery, bridging biological systems with rational design strategies.

References

1. 1.Moskalensky, A. E. (2026). Platelets as programmable drug depots: Toward predictive and mechanistic drug loading. Molecular Pharmaceutics. Advance online publication. https://doi.org/10.1021/acs.molpharmaceut.6c00430